CARSGEN-B Announces Acceptance of CT0596 and CT1190B Study Abstracts for Poster Presentation at 2026 EHA Congress

Stock News04-27

CARSGEN-B (02171) announced that the abstracts detailing the results of the IIT study for CT0596, a universal CAR-T cell product targeting BCMA for the treatment of relapsed/refractory multiple myeloma/plasma cell leukemia (R/R MM, PCL), and for CT1190B, a universal CAR-T cell product targeting CD19/CD20 for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), have been accepted for poster presentation at the 2026 European Hematology Association (EHA) Annual Meeting. The abstracts and further information will be released after 15:30 Central European Summer Time on May 12, 2026.

CT0596 is a universal CAR-T cell therapy targeting BCMA, developed using CARSGEN's proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or PCL. CT0596 has demonstrated a preliminary favorable safety profile and encouraging efficacy signals. The company also plans to further explore its application in other plasma cell neoplasms and autoimmune diseases driven by autoreactive plasma cells. The company plans to initiate a Phase Ib clinical trial for R/R MM and primary plasma cell lymphoma in 2026.

CT1190B is a universal CAR-T cell therapy targeting CD19/CD20, also developed on the THANK-u Plus™ platform. Ongoing clinical trials for CT1190B include an IIT for treating R/R B-NHL and an IIT for treating moderate-to-severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc). The company plans to commence a Phase Ib registration clinical trial for treating R/R B-NHL with this candidate in 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168987480?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168987480","market":"hk","top_or_hot":-1,"title":"CARSGEN-B Announces Acceptance of CT0596 and CT1190B Study Abstracts for Poster Presentation at 2026 EHA Congress","media":"Stock News","content":"<p>CARSGEN-B (02171) announced that the abstracts detailing the results of the IIT study for CT0596, a universal CAR-T cell product targeting BCMA for the treatment of relapsed/refractory multiple myeloma/plasma cell leukemia (R/R MM, PCL), and for CT1190B, a universal CAR-T cell product targeting CD19/CD20 for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), have been accepted for poster presentation at the 2026 European Hematology Association (EHA) Annual Meeting. The abstracts and further information will be released after 15:30 Central European Summer Time on May 12, 2026.</p>\n<p>CT0596 is a universal CAR-T cell therapy targeting BCMA, developed using CARSGEN's proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or PCL. CT0596 has demonstrated a preliminary favorable safety profile and encouraging efficacy signals. The company also plans to further explore its application in other plasma cell neoplasms and autoimmune diseases driven by autoreactive plasma cells. The company plans to initiate a Phase Ib clinical trial for R/R MM and primary plasma cell lymphoma in 2026.</p>\n<p>CT1190B is a universal CAR-T cell therapy targeting CD19/CD20, also developed on the THANK-u Plus™ platform. Ongoing clinical trials for CT1190B include an IIT for treating R/R B-NHL and an IIT for treating moderate-to-severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc). The company plans to commence a Phase Ib registration clinical trial for treating R/R B-NHL with this candidate in 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARSGEN-B Announces Acceptance of CT0596 and CT1190B Study Abstracts for Poster Presentation at 2026 EHA Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARSGEN-B Announces Acceptance of CT0596 and CT1190B Study Abstracts for Poster Presentation at 2026 EHA Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-27 19:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CARSGEN-B (02171) announced that the abstracts detailing the results of the IIT study for CT0596, a universal CAR-T cell product targeting BCMA for the treatment of relapsed/refractory multiple myeloma/plasma cell leukemia (R/R MM, PCL), and for CT1190B, a universal CAR-T cell product targeting CD19/CD20 for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), have been accepted for poster presentation at the 2026 European Hematology Association (EHA) Annual Meeting. The abstracts and further information will be released after 15:30 Central European Summer Time on May 12, 2026.</p>\n<p>CT0596 is a universal CAR-T cell therapy targeting BCMA, developed using CARSGEN's proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or PCL. CT0596 has demonstrated a preliminary favorable safety profile and encouraging efficacy signals. The company also plans to further explore its application in other plasma cell neoplasms and autoimmune diseases driven by autoreactive plasma cells. The company plans to initiate a Phase Ib clinical trial for R/R MM and primary plasma cell lymphoma in 2026.</p>\n<p>CT1190B is a universal CAR-T cell therapy targeting CD19/CD20, also developed on the THANK-u Plus™ platform. Ongoing clinical trials for CT1190B include an IIT for treating R/R B-NHL and an IIT for treating moderate-to-severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc). The company plans to commence a Phase Ib registration clinical trial for treating R/R B-NHL with this candidate in 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1168987480","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168987480","pubTimestamp":1777288360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CARSGEN-B (02171) announced that the abstracts detailing the results of the IIT study for CT0596, a universal CAR-T cell product targeting BCMA for the treatment of relapsed/refractory multiple...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股","BK1585":"昨日强势股","02171":"科济药业-B"},"translate_title":"科济康-B宣布接受CT0596和CT1190B研究摘要在2026年EHA大会上进行海报展示","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"CARSGEN-B (02171) announced that the abstracts detailing the results of the IIT study for CT0596, a universal CAR-T cell product targeting BCMA for the treatment of relapsed/refractory multiple myeloma/plasma cell leukemia (R/R MM, PCL), and for CT1190B, a universal CAR-T cell product targeting CD19/CD20 for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), have been accepted for poster presentation at the 2026 European Hematology Association (EHA) Annual Meeting. The abstracts and further information will be released after 15:30 Central European Summer Time on May 12, 2026.\nCT0596 is a universal CAR-T cell therapy targeting BCMA, developed using CARSGEN's proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or PCL. CT0596 has demonstrated a preliminary favorable safety profile and encouraging efficacy signals. The company also plans to further explore its application in other plasma cell neoplasms and autoimmune diseases driven by autoreactive plasma cells. The company plans to initiate a Phase Ib clinical trial for R/R MM and primary plasma cell lymphoma in 2026.\nCT1190B is a universal CAR-T cell therapy targeting CD19/CD20, also developed on the THANK-u Plus™ platform. Ongoing clinical trials for CT1190B include an IIT for treating R/R B-NHL and an IIT for treating moderate-to-severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc). The company plans to commence a Phase Ib registration clinical trial for treating R/R B-NHL with this candidate in 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168987480","isCrawlerRequest":true}